Bruker 8-K
EarningsGuidance reaffirmedImpairment / charge
Cost discipline expanded margins as BSI demand strengthened; FY2026 non-GAAP EPS guidance held at $2.10–$2.15.
Filed 2026-11-04 07:00 ET
- 2.02 Results of Operations
- 9.01 Financial Statements and Exhibits
Summary
Q3 2026 results with FY2026 guidance. Cost discipline and execution drove margin expansion and 24.4% Y/Y growth in non-GAAP diluted EPS.
Bruker reaffirmed FY2026 organic revenue growth and non-GAAP EPS guidance while updating its currency assumptions: foreign currency is now expected to be neutral to revenue, versus a previously expected 0.5% tailwind. For FY2027, management expects revenue growth acceleration, continued margin expansion and double-digit EPS growth.
Developments
- Bruker Scientific Instruments’ (BSI) book-to-bill ratio remained above one for a fifth consecutive quarter; its organic bookings and backlog were both up mid-single digits YTD, as the company reported strengthening demand in most end markets, including the U.S. academic market in Q3.
- Bruker highlighted post-genomic drug discovery and disease biology research, infectious disease diagnostics, and deep-tech and semiconductor metrology as growth areas.
Key Figures
| Metric | Q3 2026 | 9M 2026 |
|---|---|---|
| Revenue | $874.0M, +1.6% Y/Y | $2.54B, +3.1% Y/Y |
| GAAP gross margin | 49.1%, vs 44.1% | 48.3%, vs 45.9% |
| Non-GAAP gross margin | 51.3%, vs 50.1% | 51.1%, vs 50.0% |
| GAAP operating loss | $(91.0)M, vs $(51.8)M | $(146.1)M, vs $(8.1)M |
| Non-GAAP operating income | $142.6M, +35% Y/Y | $345.3M, +24% Y/Y |
| Net loss attributable to Bruker Corporation common shareholders | $(122.8)M, vs $(62.4)M | $(182.2)M, vs $(37.4)M |
| GAAP diluted EPS | $(0.81), vs $(0.41) | $(1.20), vs $(0.25) |
| Non-GAAP diluted EPS | $0.56, +24.4% Y/Y | $1.36, +11% Y/Y |
| Operating cash flow | $118.2M, vs $(33.2)M | $112.0M, vs $(95.7)M |
| Free cash flow | $96.7M, vs $(54.1)M | $37.5M, vs $(163.9)M |
- The $174.5M Q3 goodwill impairment contributed $1.14 per diluted share to the GAAP-to-non-GAAP adjustment; the nine-month impairment charge was $309.4M, contributing $2.04 per diluted share.
- Q3 revenue growth included 1.7% growth from acquisitions, partly offset by a 0.8% unfavorable foreign-currency impact; organic revenue grew 0.7%. BSI organic revenue declined 0.4%, while Bruker Energy & Supercon Technologies (BEST) organic revenue grew 11.8%.
- Cash and cash equivalents were $119.7M at 9/30/2026, versus $298.8M at 12/31/2025.
Guidance
| Metric | Period | Guidance | Prior | Direction |
|---|---|---|---|---|
| Reported revenue | FY2026 | $3.52B-$3.56B; 2.5%-3.5% Y/Y | — | — |
| Organic revenue growth | FY2026 | 1%-2% | — | Reaffirmed |
| M&A revenue growth | FY2026 | ≈1.5% | — | — |
| Constant exchange rate revenue growth | FY2026 | 2.5%-3.5% | — | — |
| Foreign-currency impact on revenue | FY2026 | Neutral | Previously a 0.5% tailwind | Lowered |
| Non-GAAP diluted EPS | FY2026 | $2.10-$2.15; 15%-17% Y/Y growth | — | Reaffirmed |
| Revenue growth | FY2027 | Acceleration | — | — |
| Operating margin | FY2027 | Continued expansion | — | — |
| EPS growth | FY2027 | Double-digit growth | — | — |
Guidance changes, derived from earlier filings
| Metric | Period | Earlier guidance | Guidance now | Change |
|---|---|---|---|---|
| Reported revenue | FY2026 | $3.54B–$3.57B; +3%–4% Y/Y | $3.52B-$3.56B; 2.5%-3.5% Y/Y | lowered |
| Organic revenue growth | FY2026 | 1%–2% | 1%-2% | reaffirmed |
| M&A revenue growth | FY2026 | ≈1.5% | ≈1.5% | reaffirmed |
| Constant exchange rate revenue growth | FY2026 | 2.5%–3.5% | 2.5%-3.5% | reaffirmed |
| Non-GAAP diluted EPS | FY2026 | $2.10–$2.15; +15%–17% Y/Y; ≈$0.10 currency headwind | $2.10-$2.15; 15%-17% Y/Y growth | reaffirmed |
The summary is written by an AI model reading the filing.
Model 005 · prompt v175 · 2026-11-04 15:33:57Z